Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Ilex and Symphar begin phase I studies of SR-45023A

Jan. 7, 1999

PSC-833 modulates the tumor disposition of vinca alkaloids in vitro and in vivo

Jan. 7, 1999

Angiogene's vascular-targeting agent for solid tumors enters Zeneca's development portfolio

Jan. 5, 1999

Expanded use of Photofrin approved by FDA

Jan. 4, 1999

Ajinomoto prepares potent, water-soluble combretastatin analogues

Dec. 30, 1998

IND filed by Cell Pathways for new SAAND; lead compound Prevatac enters clinic for sixth indication

Dec. 30, 1998

Water-soluble anticancer compounds available for licensing from NIH

Dec. 30, 1998

Several NDAs up for review by FDA oncologic advisory committee in January

Dec. 30, 1998

Grant to help Faulding and collaborators develop innovative prostate cancer treatment

Dec. 29, 1998

Vion pursues prodrugs of 3-AP with superior biological, pharmaceutical properties

Dec. 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...